Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human oral squamous carcinoma cells KB and KB/VCR: In vitro and in vivo studies.

@article{Yue2013RiccardinDA,
  title={Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human oral squamous carcinoma cells KB and KB/VCR: In vitro and in vivo studies.},
  author={Bin Yue and Cui-rong Zhao and Huihua Xu and Yuan-yuan Li and Yan-na Cheng and Han-Ni Ke and Yi Yuan and Rui-qi Wang and Yan-qiu Shi and Hongxiang Lou and Xian-Jun Qu},
  journal={Biochimica et biophysica acta},
  year={2013},
  volume={1830 1},
  pages={
          2194-203
        }
}
1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib.
A modified DAW-22 compound F-B1 inhibits Bcr/Abl and induces apoptosis in chronic myelogenous leukemia cells
TLDR
Experimental validation results together demonstrated that F-B1 can inhibit Bcr/Abl fusion proteins in K562 and K562G cells, implying that F -B1 might be a promising drug to treat CML, especially the imatinib-resistant CML.
Transcriptomic and Functional Pathway Analysis of Human Cervical Carcinoma Cancer Cells Response to Microtubule Inhibitor
TLDR
Transcriptional time series profiles and a functional pathway analysis of VBL-treated KB-3 cells will provide a new strategy for improving microtubule inhibitor chemotherapy for cervical carcinoma.
{2-[1-(3-Methoxycarbonylmethyl-1H-indol-2-yl)-1-methyl-ethyl]-1H-indol-3-yl}-acetic Acid Methyl Ester Inhibited Hepatocellular Carcinoma Growth in Bel-7402 Cells and Its Resistant Variants by Activation of NOX4 and SIRT3
TLDR
It is suggested that MIAM might be a promising candidate compound which could develop as a potent anticancer agent targeting NOX4 and SIRT3 activation.

References

SHOWING 1-10 OF 35 REFERENCES
Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II
TLDR
It is demonstrated that riccardin D is a novel DNA topo II inhibitor which can induce apoptosis of human leukemia cells and that it has therapeutic potential for both regular and MDR strains of leukemia cells.
Overcoming of P-glycoprotein-mediated multidrug resistance in K562/A02 cells using riccardin F and pakyonol, bisbibenzyl derivatives from liverworts.
TLDR
The potential application of bisbibenzyl type compounds as modulators of P-gp-mediated MDR in tumor cells is explored by employing K562 and K562/A02 cells, the well-known adriamycin (ADR)-induced multidrug resistance (MDR) tumor cell lines over-expressing P-glycoprotein (P-gp).
Cytotoxicity, apoptosis induction and downregulation of MDR‐1 expression by the anti‐topoisomerase II agent, salvicine, in multidrug‐resistant tumor cells
TLDR
It is shown that salvicine effectively kills multidrug‐resistant (MDR) sublines, such as K562/A02, KB/VCR and MCF‐7/ADR, and parental K562, KB and MCf‐7 cell lines to an equivalent degree and the reduction of mdr‐1 and bcl‐2 expression by salvicines possibly contributes to its cytotoxicity and apoptotic induction in this system.
A112, a tamibarotene dimethylaminoethyl ester, may inhibit human leukemia cell growth more potently than tamibarotene
TLDR
It is suggested that A112 is a highly effective derivative of trans retinoic acid and a potential candidate compound for the treatment of leukemia.
...
1
2
3
4
...